BBOT
Taking Precision Oncology to New Heights
Key Highlights
- Bridging to a Better Future in Oncology: BBOT is advancing a pipeline of potentially first- and best-in-class therapies targeting the RAS signaling pathway, including ON/OFF KRAS inhibitors and a novel PI3Kα inhibitor for two of the most frequently mutated pathways in cancer, RAS and PI3Kα. The company is redefining RAS inhibition by targeting both the ON and OFF states of RAS to enable deeper inhibition of cancer driving signals, reduce resistance, and improve safety. This next-gen approach has the potential to deliver deeper, safer and more durable responses for patients with RAS driven cancers.
- Synergy by Design: BBOT’s pipeline is designed for rational combinations – each asset targeting complimentary nodes in the RAS signaling cascade. Preclinical data (here and here) show synergy between these agents, supporting a plug-and-play strategy that could unlock deeper, more durable responses and delay resistance.
- 2026 Milestones: BBOT is well-positioned to execute on near-term data milestones for all three of its programs, which have the potential to address the needs of approximately 250,000 U.S. patients annually across breast, lung, colorectal, and pancreatic cancers, including:
- BBO-8520 (KRASG12C ON / OFF) Phase 1 monotherapy and combination with pembrolizumab data readout in Q1 2026
- BBO-10203 (RAS:PI3Kα Breaker) Phase 1 data readout in 1H 2026
- BBO-11818 (panKRAS ON / OFF) Phase 1 data readout and broader expansion datasets across BBO-8520 and BBO-10203 in 2H 2026 onward